ONCT Stock Analysis

Oncternal Therapeutics Inc - Real-time stock metrics, market data, and comprehensive analysis

Loading...

Fetching stock data...

Oncternal Therapeutics Inc

GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscles Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. In October 2012, it sold rights and related assets in the metastatic breast cancer product, Fareston, to ProStrakan Group plc.

Market Data

Current Price

$0.53

+$0.00 (0.00%)
Market Cap

-

Total Company Value
Day Range
$0.53 - $0.53
Session Volume
-
Shares traded today

Valuation Metrics

P/E Ratio

-

Price ÷ Earnings
EPS (Basic)

-

Earnings Per Share
Price-to-Book

-

Market Value ÷ Book Value

Financial Health

Revenue (TTM)

-

Trailing 12 Months
Net Income (TTM)

-

Profit After Tax
Gross Margin

-

Revenue Efficiency

Returns & Dividends

Dividend Yield

-

Annual Dividend ÷ Price
Annual Dividend

-

Per Share
Payout Ratio

-

Dividend ÷ EPS

Price Performance

Price Chart
All times are in Eastern Time (ET)

Recent News

No news available

Data Source: Financial data is sourced from SEC filings via Tiingo and may be delayed. Market Status: OPEN - Prices update every 2 minutes. (Last updated: 2:05 PM)
Logos provided by Logo.dev

Contact Me

Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.

Contact Form Demo

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.